Table 4. Multivariate analyses of OS, DFS and PFS in relation to clinical parameters and HE4 serum levels (A, entire cohort of EC patients; B, poorly differentiated EC patients).
OS
|
DFS
|
PFS
|
|||||||
---|---|---|---|---|---|---|---|---|---|
Variable | HR | 95% CI | P-value | HR | 95% CI | P-value | HR | 95% CI | P-value |
(A) | |||||||||
Lymph node involvement | |||||||||
Positive vs negative | 0.67 | 0.07–6.11 | 0.72 | 1.20 | 0.14–10.26 | 0.87 | 0.53 | 0.06–5.06 | 0.58 |
Histological type | |||||||||
Non-endometrioid vs endometrioid | 4.89 | 1.09–21.81 | 0.01 | 2.37 | 0.64–8.75 | 0.22 | 3.30 | 0.80–13.56 | 0.04 |
FIGO stage | |||||||||
III+IV vs I+II | 20.32 | 1.79–230.40 | 0.04 | 3.84 | 0.44–33.47 | 0.20 | 11.72 | 1.13–121.31 | 0.09 |
HE4 serum levels (tertiles) | |||||||||
High vs low | 2.84 | 0.54–15.01 | 0.22 | 2.80 | 0.65–12.15 | 0.17 | 2.76 | 0.47–16.14 | 0.26 |
Medium vs low | 5.35 | 0.80–35.67 | 0.08 | 3.05 | 0.69–13.51 | 0.14 | 3.18 | 0.53–19.17 | 0.21 |
(B) | |||||||||
Lymph node involvement | |||||||||
Positive vs negative | 0.55 | 0.05–5.58 | 0.62 | 1.32 | 0.14–12.30 | 0.81 | 0.54 | 0.05–6.08 | 0.62 |
Histological type | |||||||||
Non-endometrioid vs endometrioid | 1.06 | 0.21–5.29 | 0.04 | 0.75 | 0.16–3.55 | 0.31 | 0.98 | 0.22–4.39 | 0.07 |
FIGO stage | |||||||||
III+IV vs I+II | 14.38 | 1.13–183.28 | 0.94 | 3.36 | 0.32–35.47 | 0.71 | 10.06 | 0.81–125.71 | 0.98 |
HE4 serum levels (tertiles) | |||||||||
High vs low | 6.85 | 1.02–46.17 | 0.04 | 17.00 | 1.89–153.24 | 0.01 | 9.81 | 1.01–95.26 | 0.04 |
Medium vs low | 4.98 | 0.80–31.06 | 0.08 | 5.10 | 0.50–51.00 | 0.17 | 6.74 | 0.72–62.54 | 0.09 |
Abbreviations: CI=confidence interval; DFS=disease-free survival; EC=endometrial carcinoma; FIGO=International Federation of Gynecology and Obstetrics; HE4=human epididymis protein 4; HR=hazards ratio; OS=overall survival; PFS=progression-free survival; WHO=World Health Organisation.